One Turn Open the globe →

Health · Silver Spring, United States · United States of America ·

FDA approves generic twice-yearly HIV prevention shot

Reported by 2 outlets · first reported Nov 2, 4:58 PM ET

The FDA approved the first generic lenacapavir, a twice-yearly HIV prevention injection. It is expected to cost about $40 a year in 120 low- and middle-income countries.

Why it matters

Cheap access could greatly cut new HIV infections in poorer countries.

Background

Lenacapavir was the world's only twice-yearly HIV prevention shot.

The story so far

  1. FDA approves first generic twice-yearly HIV prevention shot
  2. FDA approves generic twice-yearly HIV prevention shot
  3. FDA approves low-cost HIV prevention shot

Follow the whole story →

Sources

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.

See it on the globe →All of Nov 3's stories

More on health